Advertisement

Chinese Journal of Integrative Medicine

, Volume 18, Issue 7, pp 539–542 | Cite as

Drug discovery enters a new era with multi-target intervention strategy

  • Xiao-ying Tian (田晓英)
  • Liang Liu (刘 良)
Academic Exploration

Abstract

In the past century, as medical research has become increasingly precise, it has become clear that the incidence and progression of many diseases involve multiple factors and pathologies; this is particularly true for the degenerative and metabolic diseases facing industrialized societies. At the same time, it becomes increasingly clear that single-target action drugs cannot effectively treat these diseases. Researchers are looking toward the chemical industry as well as traditional herbal medicines to find multi-target interventions. Thus, a new era in drug discovery has begun. Specifically, three approaches have proven effective in seeking multi-target drugs. These are: (1) designing drugs with multiple components; (2) discovering drugs through the study of synergistic compound-compound interactions in medicinal herbs or among chemical drugs and herbal components; and (3) developing drugs to tackle complex multi-component diseases. The authors conclude that there is an increasing need for multi-component remedies to treat the complex chronic diseases afflicting modern populations. Given this situation and the growing body of evidence that these new approaches are effective, multi-target intervention appears to have great potential for discovering, designing, and developing effective new drugs for today’s diseases.

Keywords

multi-target intervention compound-compound interaction herb-drug interaction synergy multi-component remedy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005;4:71–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Zhang QY, Mao JH, Liu P, Huang QH, Lu J, Xie YY, et al. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci USA 2009;106:3378–3383.PubMedCrossRefGoogle Scholar
  3. 3.
    Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 2000;97:1433–1437.PubMedCrossRefGoogle Scholar
  4. 4.
    Liu ZQ, Zhou H, Liu L, Jiang ZH, Wong YF, Xie Y, et al. Influence of co-administrated sinomenine on pharmacokinetic fate of paeoniflorin in unrestrained conscious rats. J Ethnopharmacol 2005;99:61–67.PubMedCrossRefGoogle Scholar
  5. 5.
    Liu ZQ, Jiang ZH, Liu L, Hu M. Mechanisms responsible for poor oral bioavailability of paeoniflorin: role of intestinal disposition and interactions with sinomenine. Pharm Res 2006;23:2768–2780.PubMedCrossRefGoogle Scholar
  6. 6.
    Chan K, Liu ZQ, Jiang ZH, Zhou H, Wong YF, Xu HX, et al. The effects of sinomenine on intestinal absorption of paeoniflorin by the everted rat gut sac model. J Ethnopharmacol 2006;103:425–432.PubMedCrossRefGoogle Scholar
  7. 7.
    Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552–556.PubMedCrossRefGoogle Scholar
  8. 8.
    Land H, Chen AC, Morgenstern JP, Parada LF, Weinberg RA. Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol 1986;6:1917–1925.PubMedGoogle Scholar
  9. 9.
    Dotto GP, Parada LF, Weinberg RA. Specific growth response of ras-transformed embryo fibroblasts to tumour promoters. Nature 1985;318:472–475.PubMedCrossRefGoogle Scholar
  10. 10.
    Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596–602.PubMedCrossRefGoogle Scholar
  11. 11.
    Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy—from TCM theory to mechanistic insights. Planta Med 2010;76:1118–1131.PubMedCrossRefGoogle Scholar
  12. 12.
    Macián F, García-Cózar F, Im SH, Horton HF, Byrne MC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 200 2002;109:719–731.CrossRefGoogle Scholar
  13. 13.
    Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L. Matrine induces cell anergy in human Jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated T-cells signaling with concomitant up-regulation of anergy-associated genes expression. Biol Pharm Bull 2010;33:40–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L. Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF-kappaB signaling pathway and p38 phosphorylation. J Cell Biochem 2009;108:87–95.PubMedCrossRefGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Xiao-ying Tian (田晓英)
    • 1
  • Liang Liu (刘 良)
    • 1
    • 2
  1. 1.Centre for Cancer and Inflammation Research, School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina
  2. 2.State Key Laboratory for Quality Research in Chinese MedicinesMacau University of Science and TechnologyTaipa, MacauChina

Personalised recommendations